Stryker Co. (NYSE:SYK) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lessened its stake in shares of Stryker Co. (NYSE:SYK) by 1.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 42,313 shares of the medical technology company’s stock after selling 537 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Stryker were worth $15,286,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Centennial Bank AR boosted its position in Stryker by 106.7% during the second quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after acquiring an additional 48 shares during the last quarter. Hara Capital LLC purchased a new position in shares of Stryker in the 3rd quarter worth about $42,000. HBW Advisory Services LLC acquired a new stake in Stryker during the third quarter valued at approximately $42,000. Grove Bank & Trust lifted its holdings in Stryker by 84.8% during the 3rd quarter. Grove Bank & Trust now owns 122 shares of the medical technology company’s stock worth $44,000 after buying an additional 56 shares during the last quarter. Finally, DT Investment Partners LLC increased its holdings in shares of Stryker by 114.3% in the 3rd quarter. DT Investment Partners LLC now owns 135 shares of the medical technology company’s stock valued at $49,000 after acquiring an additional 72 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Stryker

In related news, insider Viju Menon sold 600 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now owns 9,069 shares in the company, valued at approximately $3,219,495. This represents a 6.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares in the company, valued at approximately $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 67,381 shares of company stock valued at $24,825,275 in the last three months. 5.90% of the stock is currently owned by corporate insiders.

Stryker Price Performance

Shares of NYSE:SYK opened at $390.08 on Friday. The stock’s 50 day moving average price is $364.07 and its 200 day moving average price is $347.40. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. The stock has a market cap of $148.71 billion, a price-to-earnings ratio of 41.81, a PEG ratio of 2.94 and a beta of 0.91. Stryker Co. has a 12 month low of $282.35 and a 12 month high of $392.70.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The firm had revenue of $5.49 billion for the quarter, compared to analysts’ expectations of $5.37 billion. During the same period in the previous year, the business earned $2.46 earnings per share. Stryker’s revenue for the quarter was up 11.9% compared to the same quarter last year. Equities research analysts anticipate that Stryker Co. will post 12.06 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on SYK. Barclays boosted their target price on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. StockNews.com raised Stryker from a “hold” rating to a “buy” rating in a report on Thursday. Royal Bank of Canada increased their price target on Stryker from $386.00 to $400.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Robert W. Baird boosted their price objective on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. increased their target price on Stryker from $375.00 to $420.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and a consensus target price of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.